|
業務類別
|
Biotechnology |
|
業務概覽
|
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. |
| 公司地址
| 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560 |
| 電話號碼
| +1 212 554-4484 |
| 傳真號碼
| +1 212 554-4531 |
| 公司網頁
| https://www.tgtherapeutics.com |
| 員工數量
| 399 |
| Mr. Michael S. Weiss |
Chairman of the Board, Chief Executive Officer and President |
美元 875.00K |
30/04/2026 |
| Mr. Sean A. Power |
Chief Financial Officer, Treasurer and Corporate Secretary |
美元 500.00K |
30/04/2026 |
|
|
| Mr. Laurence N. Charney |
Lead Independent Director |
30/04/2026 |
| Mr. Michael S. Weiss |
Chairman of the Board, Chief Executive Officer and President |
30/04/2026 |
| Dr. Yann Echelard, PhD |
Independent Director |
30/04/2026 |
| Mr. Kenneth Hoberman |
Independent Director |
30/04/2026 |
| Mr. Daniel Hume |
Independent Director |
30/04/2026 |
| Dr. Sagar Lonial, M.D. |
Independent Director |
30/04/2026 |
|
|
|
|
